Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TtbioROCO:6493 -5.15%60 Gross Margin % is 14.42% as of Dec. 2025, which is 51% below its 10-year median of 29.43. GuruFocus rates ROCO:6493 with a GF Score™ of 60/100 and a GF Value™ of NT$19.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Ttbio ranks worse than 90.94% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Ttbio's Gross Profit for the
six
months ended in Dec. 2025 was NT$26.8 Mil. Ttbio's Revenue for the
six
months ended in Dec. 2025 was NT$186.0 Mil. Therefore, Ttbio's Gross Margin % for the quarter that ended in Dec. 2025 was 14.42%.
Warning Sign:
Ttbio Corp gross margin has been in long-term decline. The average rate of decline per year is -8.4%.
The historical rank and industry rank for Ttbio's Gross Margin % or its related term are showing as below:
ROCO:6493'
s Gross Margin % Range Over the Past 10 Years
Min: 17.63 Med: 29.43 Max: 40.88
Current: 17.63
During the past 13 years, the highestGross Margin % of Ttbio was 40.88%. The lowest was 17.63%. And the median was 29.43%.
ROCO:6493's Gross Margin % is ranked worse than 90.94% of 806
companies
in the Medical Devices & Instruments industry
Industry Median: 52.05
vs ROCO:6493: 17.63
Ttbio had a gross margin of 14.42% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Ttbio was -8.40% per year.
Ttbio (ROCO:6493) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ttbio had a gross margin of 14.42% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ttbio Gross Margin % Related Terms
Ttbio Gross Margin % Historical Data
* Premium members only.
The historical data trend for Ttbio's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6493 vs ISRG, BDX, MDLN: Gross Margin % Comparison
For the Medical Instruments & Supplies subindustry, Ttbio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ttbio Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ttbio's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ttbio's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ttbio (ROCO:6493) has a Gross Margin % of 14.42% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Ttbio and its competitors. This is 51% below median its historical median of 29.43. Over the past decade, Ttbio's Gross Margin % has ranged from 17.63 to 40.88. According to the industry distribution chart, Ttbio ranks #733 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 90.9%.
Is Ttbio's Gross Margin % too high?
Ttbio's current Gross Margin % of 14.42% is 51% below median its 10-year median of 29.43. Over the past 10 years, this metric has ranged from a low of 17.63 to a high of 40.88. The Medical Devices & Instruments industry median Gross Margin % is 52.05. Ttbio's value of 14.42% is 72.3% below this industry median. Based on the distribution chart, Ttbio ranks #733 out of 806 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ttbio has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ttbio's Gross Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ttbio ranks #733 out of 806 companies for Gross Margin %. This places Ttbio in the lower half of its industry. The industry median Gross Margin % is 52.05. Ttbio's value of 14.42% is 72.3% below this benchmark. Historically, Ttbio's own Gross Margin % has ranged from 17.63 to 40.88 over the past decade. While the company's 10-year median is 29.43 vs. the industry median of 52.05, Ttbio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.05, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ttbio's current Gross Margin % of 14.42% is 72.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ttbio and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ttbio's current Gross Margin % is 14.42%, which is 51% below median its own 10-year median of 29.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ttbio stock overvalued right now?
Based on GuruFocus' analysis, Ttbio (ROCO:6493) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$19.62, compared to a current price of NT$48.85 — trading 149% above its estimated fair value. The current Gross Margin % is 14.42%, which is 51% below median its 10-year median of 29.43 and 72.3% below the Medical Devices & Instruments industry median of 52.05. Ttbio's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ttbio (ROCO:6493), the current Gross Margin % is 14.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ttbio (ROCO:6493) Overvalued in 2026?
Based on GuruFocus' analysis, Ttbio stock appears to be overvalued.
The current stock price of NT$48.85 is trading 149% above its estimated GF Value™ of NT$19.62.
GuruFocus considers Ttbio to be Significantly Overvalued.
Key valuation signals for ROCO:6493:
Gross Margin %: 14.42% (51% below median its 10-year median of 29.43)
GF Value™: NT$19.62 vs. price of NT$48.85 (149% above fair value)
Industry Position: 72.3% below the Medical Devices & Instruments median (#733 of 806)
No single metric tells the full story. See the ROCO:6493 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ttbio Corp is a Taiwan based company engaged in the manufacturing of dental products and accessories. Its products include High-Speed Handpiece Series, Low-Speed Handpiece Series, Dental Spare Parts, Service Rotor, and Maintenance Unit among others.
60GF Score
Get the complete analysis for ROCO:6493
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6493 has been successfully added to your 
